Tezacaftor and Ivacaftor generic Tezacaftor and Ivacaftor tablets in combination therapy and ivacaftor as a monotherapy are prescribed in patients 12 years and older who are suffering from cystic fibrosis (CF). The condition is due to one or two F508del mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If the patient’s genotype is not known, the patient can be treated by confirming the cystic fibrosis gene mutation by an FDA-cleared CF mutation test followed by verification with bi-directional sequencing.
More Info about Tezacaftor and Ivacaftor